RxDoctor Payments Data

Donna Prater

Family · Waynesboro, TNNPI 1982031415

Payments from drug & device makers

$2,979in general payments, 2019–2025

Across 96 payments — averaging $31.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$2K
  • AbbVie$437
  • Johnson & Johnson$204
  • Medtronic$151
  • Novo Nordisk$118
  • AstraZeneca$81
  • plus $221 from 8 others

What the payments were for

  • Travel & lodging$1,38847%
  • Food & beverage$1,59153%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,979 in reported general payments places this provider in the 80th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$53,420
Medicare patients
116
Services billed
1,944

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cosentyx Sensoready (2 Pens)Secukinumab15$107,759
OzempicSemaglutide78$86,025
EliquisApixaban65$46,321
TrulicityDulaglutide19$25,199
MounjaroTirzepatide21$21,981
JardianceEmpagliflozin22$21,735
XareltoRivaroxaban24$16,618
FarxigaDapagliflozin Propanediol32$15,419
LinzessLinaclotide26$14,695
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$8,490
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen302$7,439
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr14$6,435
Breo ElliptaFluticasone/Vilanterol12$4,572
Albuterol Sulfate HfaAlbuterol Sulfate157$3,310
Lantus SolostarInsulin Glargine,hum.Rec.Anlog23$3,236

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$118$86,02578 claims
PfizerEliquis, Premarin$32$48,29779 claims
Boehringer IngelheimJardiance$51$21,73522 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$41$19,49737 claims
Johnson & JohnsonXarelto$204$16,61824 claims
AbbVieLinzess, Synthroid$437$16,55561 claims
AstraZenecaFarxiga$81$15,41932 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 6,706 family providers in Tennessee.

Other family in Waynesboro

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →